These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26192307)

  • 1. A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions.
    Crisponi G; Nurchi VM; Crespo-Alonso M; Sanna G; Zoroddu MA; Alberti G; Biesuz R
    PLoS One; 2015; 10(7):e0133050. PubMed ID: 26192307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ; Kolnagou A
    Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR; Martin MB
    N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y; Evans P; Manz CY; Porter JB
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term trials of deferiprone in Cooley's anemia.
    Olivieri NF; Brittenham GM
    Ann N Y Acad Sci; 1998 Jun; 850():217-22. PubMed ID: 9668542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
    Sooriyaarachchi M; Gailer J
    Dalton Trans; 2010 Aug; 39(32):7466-73. PubMed ID: 20623073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
    Berdoukas V; Chouliaras G; Moraitis P; Zannikos K; Berdoussi E; Ladis V
    J Cardiovasc Magn Reson; 2009 Jun; 11(1):20. PubMed ID: 19558722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM; Nathan DG; Olivieri NF; Pippard MJ; Weatherall DJ
    Lancet; 2003 Jan; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT; Warburton F; Christou S; Hadjigavriel M; Sitarou M; Kolnagou A; Angastiniotis M
    Haematologica; 2009 Dec; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract]   [Full Text] [Related]  

  • 19. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G; Lindeman R
    Br J Haematol; 2008 Aug; 142(4):679-80. PubMed ID: 18537970
    [No Abstract]   [Full Text] [Related]  

  • 20. Zinc(II) and copper(II) complexes with hydroxypyrone iron chelators.
    Lachowicz JI; Nurchi VM; Crisponi G; Jaraquemada-Pelaez Mde G; Ostrowska M; Jezierska J; Gumienna-Kontecka E; Peana M; Zoroddu MA; Choquesillo-Lazarte D; Niclós-Gutiérrez J; González-Pérez JM
    J Inorg Biochem; 2015 Oct; 151():94-106. PubMed ID: 26281974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.